News – KACTUS

Festival of Biologics 2023

MEET KACTUS AT THE FESTIVAL OF BIOLOGICS 2023. San Diego, CA March 20-22 Booth #55 What is Festival of Biologics? Festival of Biologics u...

New target for colorectal cancer: GPA33

Colorectal cancer (CRC) is the third most common tumor and the most common tumor of the digestive system. With the advancement of medical intervent...

Potential drug target for tumors: CDCP1

The process of tumor cell infiltration, adhesion and migration is an important research direction in the process of drug development. CUB domain co...

Cell and antibody therapies targeting HLA-G

On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001, an anti-HLA-G CAR-T cell therapy developed by Invect...

A next-generation immunotherapy target TNFR2

The tumor necrosis factor (TNF) superfamily has important physiological significance in immune surveillance, tumor regression, resistance to infect...

New Products February 2023

Alkaline Phosphatase Alkaline Phosphatase (ALP) likely represents the most frequently assayed enzyme in all of medicine. It is widely distributed ...

TIDES Asia 2023

March 7-9th 2023: Meet us at TIDES Asia in Kyoto, Japan KACTUS will be at TIDES Asia in Kyoto at booth #12 on March 7-9th. TIDES is a prominent con...

GARP-TGF-β1 Monoclonal Antibody Clinical Trial Approved by FDA

On January 4, 2023, Shanghai Jiyu Pharmaceutical announced that the IND application for its Class 1 drug JYB1907, GARP-TGF-β1 monoclonal antibody i...

Focus on hematoma target FLT3

About FLT3 Fms-like tyrosine kinase 3 (FLT3) is also known as CD135 (Cluster of differentiation antigen 135) and FLK2 (Fetal liver kinase-2). It is...

DKK1: A Wnt Pathway Regulator

DKK1 (Dickkopf-related protein 1, or Soggy) is a secreted glycoprotein that contains two conserved cysteine-rich domains CRD-1 and CRD-2 (also know...

BsaI and T7 RNA Polymerase of KACTUS Pass FDA DMF Filing

After successful completion of DMF filings for our CRISPR Cas9 enzyme and Maxnuclease in the first half of 2022, we are excited to add two new ...

TCR therapy targeting MAGE-A4

Figure 1. MAGE-A4 Protein Recently at the 2022 CTOS Conference, Adaptimmune announced the SPEARHEAD-1 clinical trial data of its TCR-T therapy, A...